Key Takeaways
- • Michael Novogratz, former Goldman Sachs partner and hedge fund manager, publicly predicted psychedelics will become "the next short-term bubble" following cannabis, citing the positive medicinal narrative driving investor interest.
- • Novogratz has backed UK-based Compass Pathways, a biotech company developing psilocybin-derived treatments for depression and other conditions, and predicted the company will achieve a public listing before year-end 2020.
- • Compass Pathways raised a $32 million Series A funding round in October 2018 and counts heavyweight investors including Peter Thiel and Moore Capital among its backers, alongside advisory support from Tom Insel (former NIMH director) and David Nutt (former UK drug czar).
- • Leading academic institutions including Johns Hopkins have established research programs investigating psychedelic compounds—including psilocybin, MDMA, and ketamine—for therapeutic applications spanning depression, obesity, Alzheimer's disease, and smoking cessation.
- • The psychedelics sector is emerging as a potential mainstream investment thesis, with Novogratz's remarks at the Context Summits conference in Miami signaling growing institutional appetite for the space.
Summary
Michael Novogratz, the veteran hedge fund manager and former Goldman Sachs partner, has positioned psychedelics as the next investment bubble, drawing parallels to the cannabis sector's trajectory. Speaking at the Context Summits conference held at the Fontainebleau Hotel in Miami on January 30, 2020, Novogratz articulated a bullish stance on the emerging psychedelics market, stating: "I'm positive this will be the next short-term bubble because it's such a positive story."
Novogratz's conviction extends beyond commentary to capital deployment. He has invested in Compass Pathways, a London-based biotech firm focused on clinical development of psilocybin-derived therapeutics for mental health disorders. Novogratz predicted Compass Pathways will complete an initial public offering before the end of 2020, though a company spokesperson declined to confirm the timeline, stating only that management is "always looking at options to ensure continued growth and funding." Compass Pathways raised $32 million in its Series A round in October 2018 and has secured backing from prominent venture investors including Peter Thiel and Moore Capital.
The scientific foundation underpinning the sector's momentum is substantive. Tier-one research institutions, notably Johns Hopkins University, have established dedicated research programs examining the therapeutic potential of psychedelic compounds including psilocybin, MDMA, and ketamine across a range of indications—depression, obesity, Alzheimer's disease, and smoking cessation among them. Compass Pathways benefits from high-caliber advisory talent, including Tom Insel, former director of the National Institutes of Mental Health, and David Nutt, the former UK government drug czar.
Novogratz's thesis reflects a broader market recognition that psychedelic compounds, long marginalized by regulatory constraints, are experiencing renewed scientific legitimacy and institutional acceptance. The framing of psychedelics as a "short-term bubble" suggests near-term capital appreciation potential, consistent with the venture and hedge fund community's appetite for early-stage biotechnology trends positioned at the intersection of therapeutic innovation and regulatory tailwinds.
Novogratz's conviction extends beyond commentary to capital deployment. He has invested in Compass Pathways, a London-based biotech firm focused on clinical development of psilocybin-derived therapeutics for mental health disorders. Novogratz predicted Compass Pathways will complete an initial public offering before the end of 2020, though a company spokesperson declined to confirm the timeline, stating only that management is "always looking at options to ensure continued growth and funding." Compass Pathways raised $32 million in its Series A round in October 2018 and has secured backing from prominent venture investors including Peter Thiel and Moore Capital.
The scientific foundation underpinning the sector's momentum is substantive. Tier-one research institutions, notably Johns Hopkins University, have established dedicated research programs examining the therapeutic potential of psychedelic compounds including psilocybin, MDMA, and ketamine across a range of indications—depression, obesity, Alzheimer's disease, and smoking cessation among them. Compass Pathways benefits from high-caliber advisory talent, including Tom Insel, former director of the National Institutes of Mental Health, and David Nutt, the former UK government drug czar.
Novogratz's thesis reflects a broader market recognition that psychedelic compounds, long marginalized by regulatory constraints, are experiencing renewed scientific legitimacy and institutional acceptance. The framing of psychedelics as a "short-term bubble" suggests near-term capital appreciation potential, consistent with the venture and hedge fund community's appetite for early-stage biotechnology trends positioned at the intersection of therapeutic innovation and regulatory tailwinds.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.